Silence Therapeutics (SLN) Revenue (2024 - 2026)

Silence Therapeutics has reported Revenue for 3 years, with the latest figure at $422000.0 in Q1 2026.

• Quarterly Revenue rose 197.18% year-over-year to $422000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $839000.0 (down 96.98% YoY) and the FY2025 annual result came in at $559000.0, down 98.71% from the prior year.
• Revenue grew to $422000.0 in Q1 2026 per SLN's latest filing, from $34000.0 in the prior quarter.
• Over five years, Revenue peaked at $25.3 million in Q4 2024 and troughed at $34000.0 in Q4 2025.
• A 3-year average of $4.9 million and a median of $422000.0 in 2026 frame the typical range for Revenue.
• The sharpest annual moves came in 2025 and 2026: Revenue plunged 99.87% in 2025, then surged 197.18% in 2026.
• Over 3 years, Revenue stood at $25.3 million in 2024, then slumped by 99.87% to $34000.0 in 2025, then jumped by 1141.18% to $422000.0 in 2026.
• According to Business Quant data, Revenue over the past three periods registered $422000.0, $34000.0, and $159000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.